Treatment of HSV-related pathologies using plasmids that make ssDNA

Abstract

A composition for treatment of HSV-related pathologies including an expression vector for altering expression of a target sequence in an HSV-infected cell by production of single-stranded cDNA (ssDNA) in the cell in vivo suspended for topical application to an affected site in a suitable delivery vehicle. The expression vector is comprised of a cassette comprising a sequence of interest, an inverted tandem repeat, and a primer binding site 3′ to the inverted tandem repeat, and a reverse transcriptase/RNAse H coding gene, and is transfected into the infected cells for inhibition of HSV replication. The resulting ssDNA binds to the target sequence to alter expression of the target sequence for such purposes as gene activation or inactivation using duplex or triplex binding of nucleic acids, site-directed mutagenesis, interruption of cellular function by binding to specific cellular proteins, or interfering with RNA splicing functions.

1 . A topical composition for the treatment of HSV-related pathologies comprising:
 (a) a single-stranded DNA (ssDNA) expression vector, wherein the vector is either pssXE or pssXV, having a gene encoding for a reverse transcriptase (RT) and a ssDNA expression cassette comprising in 5′ to 3′ order:
 (i) a cytomegalovirus (CMV) or Rouse Sarcoma virus (RSV) promoter sequence, 
 (ii) an inverted tandem repeat (IR) sequence, 
 (iii) a sequence of interest comprising SEQ ID NO: 4, and 
 (iv) a mammalian reverse transcriptase primer binding site (PBS) sequence; and 
   (b) a topical ointment or cream,   
       wherein the ssDNA so produced has minimal flanking sequence. 
     
     
         2 . The composition of  claim 1  in which the RT is mouse Maloney reverse transcriptase (MoMuLV-RT). 
     
     
         3 . The composition of  claim 1  in which the promoter is either a cytomegalovirus (CMV) or a Rouse Sarcoma virus (RSV) promoter. 
     
     
         4 . The composition of  claim 1  in which the IR sequence comprises SEQ ID NO: 10. 
     
     
         5 . The composition of  claim 1  in which the PBS site on the transcribed mRNA promotes binding of the MoMuLV-RT with an appropriate tRNA. 
     
     
         6 . The composition of  claim 1  additionally comprising an antibiotic. 
     
     
         7 . The composition of  claim 1  additionally comprising either or both of an anaesthetic or analgesic. 
     
     
         8 . The composition of  claim 1  additionally comprising one or more of vitamins A, D, and E. 
     
     
         9 . The composition of  claim 1  wherein said ointment or cream comprises a two-part gel, a Base PCCA Cosmetic HRT, or PLO. 
     
     
         10 . A method for treatment of HSV-related pathologies involving the application of a composition comprising an in vivo ssDNA expression vector, wherein the vector is either pssXE or pssXV, carrying SEQ ID NO: 4, to an affected site. 
     
     
         11 . The method of  claim 11  wherein the composition includes a topical ointment, a topical cream, or a topical spray. 
     
     
         12 . The composition of  claim 1  in which the sequence of interest comprises one or more sequences having SEQ ID NO: 4. 
     
     
         13 . The composition of  claim 1  wherein the carrier is designed for topical administration.